{
  "title": "The opioid business plan",
  "description": "Insys Therapeutics was an opioid startup that made lots of money for its addictive nasal spray. Today, we hear from Evan Hughes, author of the book <em>Hard Sell: Crime and Punishment at an Opioid Startup</em>, on how the company's carelessness led to its ultimate downfall.<br/>",
  "pubDate": "Tue, 25 Jan 2022 18:57:35 -0500",
  "copyright": "Copyright 2015-2021 NPR - For Personal Use Only",
  "guid": "10d981bc-998e-4517-bd22-41f132ff219b",
  "link": "https://www.npr.org/2022/01/14/1073199358/the-opioid-business-plan",
  "itunes:title": "The opioid business plan",
  "itunes:author": "NPR",
  "itunes:summary": "Insys Therapeutics was an opioid startup that made lots of money for its addictive nasal spray. Today, we hear from Evan Hughes, author of the book <em>Hard Sell: Crime and Punishment at an Opioid Startup</em>, on how the company's carelessness led to its ultimate downfall.<br/>",
  "itunes:image": "",
  "itunes:duration": 584,
  "itunes:explicit": "no",
  "itunes:episodeType": "full",
  "content:encoded": "Insys Therapeutics was an opioid startup that made lots of money for its addictive nasal spray. Today, we hear from Evan Hughes, author of the book <em>Hard Sell: Crime and Punishment at an Opioid Startup</em>, on how the company's carelessness led to its ultimate downfall.<br/>",
  "enclosure": ""
}